- Malvern Instruments Publishes New White Paper on ‘Developing a Bioformulation Stability Profile’ to Coincide with PepTalk 2014
Product News: Malvern Instruments Publishes New White Paper on ‘Developing a Bioformulation Stability Profile’ to Coincide with PepTalk 2014Malvern Instruments’ range of analytical solutions for the biopharmaceuticals industry focuses specifically on critical testing pathways and manufacturing requirements. As well as exhibiting solutions from its growing analytical toolbox at PepTalk 2014 (January 13-17, 2014; Palm Springs, CA), Malvern will publish a new white paper that discusses the combined use of light scattering and microcapillary viscometry in the development of a bioformulation stability profile. Copies will be available on Malvern’s Booth #315 at PepTalk 2014 and will be downloadable from the Malvern website after the event. Click on the company website link below to visit Malvern Instruments.
This new publication, ‘Developing a bioformulation stability profile’ is issued through Malvern’s Bioscience Development Initiative, which has been established to accelerate the innovation, development and promotion of novel technologies, products and capabilities to address unmet measurement needs in the bioscience arena.
Malvern’s analytical toolbox for biopharmaceutical development provides tried and trusted solutions as well as groundbreaking new technologies. Established systems include Viscotek size exclusion chromatographs for assessing product purity and the Zetasizer range for sizing and zeta potential analysis for product stability. New to the Malvern range are the Viscosizer 200, designed to assess bioformulation suitability and stability at points at the very beginning of development, together with Archimedes, Morphologi and the NanoSight ranges of instruments to quantify early aggregation and improve subvisible particle detection and identification in bioformulations.
Visit the Malvern booth #315 at PepTalk to collect a copy of ‘‘Developing a bioformulation stability profile’ or visit the Malvern website for further details of Malvern’s biopharmaceuticals portfolio.